{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:35Z","timestamp":1790657795369,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271378"],"award-info":[{"award-number":["82271378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3501304"],"award-info":[{"award-number":["2022YFC3501304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23944","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T12:12:40Z","timestamp":1703333560000},"page":"e23944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Fan","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-qi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8190-4022","authenticated-orcid":false,"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-8017","authenticated-orcid":false,"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2023.e23944_bib1","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23944_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib3","unstructured":"World Health Organization. Coronavirus disease (COVID-19) dashboard. Available from: https:\/\/covid19.who.int."},{"issue":"10239","key":"10.1016\/j.heliyon.2023.e23944_bib4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e23944_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107374","article-title":"COVID-19 vaccination in people with multiple sclerosis, real-life experience","volume":"220","author":"Alroughani","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"10267","key":"10.1016\/j.heliyon.2023.e23944_bib6","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.heliyon.2023.e23944_bib7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.heliyon.2023.e23944_bib8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23944_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e23944_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1212\/WNL.0000000000012578","article-title":"COVID-19 and vaccination in the setting of neurologic disease: an emerging issue in neurology","volume":"97","author":"Marsh","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23944_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41386-019-0463-z","article-title":"Sleep and neurological autoimmune diseases","volume":"45","author":"Iranzo","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23944_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102939","article-title":"COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies","volume":"52","author":"Garjani","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1103020","article-title":"The safety of COVID-19 vaccines in patients with myasthenia gravis: a scoping review","volume":"13","author":"Peng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","article-title":"Vaccines, adjuvants and autoimmunity","volume":"100","author":"Guimar\u00e3es","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23944_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23944_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.48.2.312","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis","volume":"48","author":"Miller","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23944_bib18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23944_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ene.15147","article-title":"Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series","volume":"29","author":"Kaulen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104167","article-title":"Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis","author":"Kong","year":"2022","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23944_bib21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ene.15348","article-title":"Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience","volume":"29","author":"Farina","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib22","first-page":"57","article-title":"COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders","author":"Jovicevic","year":"2022","journal-title":"Multiple Sclerosis and Related Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1141983","article-title":"Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study","volume":"14","author":"Ruan","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23944_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.amjmed.2017.10.033","article-title":"Autoimmune neurologic disorders","volume":"131","author":"Rubin","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.heliyon.2023.e23944_bib25","doi-asserted-by":"crossref","unstructured":"Seung Won Lee, Min Ji Koo PRISMA 2020 statement and guidelines for systematic review and meta-analysis articles, and their underlying mathematics: Life Cycle Committee Recommendations. https:\/\/doi.org\/10.54724\/lc.2022.e9.","DOI":"10.54724\/lc.2022.e9"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23944_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Base Ment. Health"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23944_bib27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Multiple Sclerosis J."},{"issue":"43","key":"10.1016\/j.heliyon.2023.e23944_bib28","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/j.vaccine.2021.09.030","article-title":"Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV","volume":"39","author":"Ali sahraian","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2023.e23944_bib29","first-page":"768","article-title":"COVID-19 vaccine reactogenicity in persons with multiple sclerosis","author":"Briggs","year":"2021","journal-title":"Multiple Sclerosis J."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23944_bib30","first-page":"E14","article-title":"SARS-CoV-2 infection and vaccination outcomes in multiple sclerosis","volume":"12","author":"Brunn","year":"2022","journal-title":"Neurology: Clin. Pract."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23944_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","article-title":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","volume":"19","author":"Capone","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.heliyon.2023.e23944_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103690","article-title":"Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis","volume":"59","author":"Ciampi","year":"2022","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23944_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/20552173221085242","article-title":"Perspectives and experiences with COVID-19 vaccines in people with MS","volume":"8","author":"Ciotti","year":"2022","journal-title":"Multiple Sclerosis J.-Experimental Transl. Clinical"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23944_bib34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp-2021-327200","article-title":"mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis","volume":"93","author":"Di filippo","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.heliyon.2023.e23944_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103424","article-title":"Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD","volume":"58","author":"Dinoto","year":"2022","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23944_bib36","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1007\/s00415-022-11303-8","article-title":"BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves","volume":"269","author":"Doron","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","author":"Dreyer-alster","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23944_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2041945","article-title":"Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis","volume":"18","author":"Etemadifar","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23944_bib39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mus.27703","article-title":"Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis","volume":"66","author":"Gamez","year":"2022","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23944_bib40","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1007\/s00415-022-11142-7","article-title":"Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study","volume":"269","author":"Giannoccaro","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103708","article-title":"Safety of Sinopharm vaccine for people with Multiple Sclerosis: study of adverse reactions and disease activity","volume":"61","author":"Kavosh","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib42","article-title":"Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: a survey-based study","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23944_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nmd.2022.01.013","article-title":"Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis","volume":"32","author":"Lotan","year":"2022","journal-title":"Neuromuscul. Disord."},{"issue":"22","key":"10.1016\/j.heliyon.2023.e23944_bib44","first-page":"11","article-title":"The safety profile of COVID-19 vaccines in patients diagnosed with multiple sclerosis: a retrospective observational study","author":"Maniscalco","year":"2022","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23944_bib45","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1007\/s00415-022-11003-3","article-title":"Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis","volume":"269","author":"Mariottini","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib46","article-title":"COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis","author":"Peric","year":"2022","journal-title":"Acta Neurol. Belg."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23944_bib47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/mus.27657","article-title":"Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis","volume":"66","author":"Pincheira","year":"2022","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23944_bib48","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/jnnp-2021-328197","article-title":"Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab","volume":"93","author":"Rauber","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23944_bib49","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200002","article-title":"Immune response and safety of SARS-CoV-2 mRNA-1273 vaccine in patients with myasthenia gravis","volume":"9","author":"Reyes-leiva","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2023.e23944_bib50","first-page":"65","article-title":"To be or not to be vaccinated: the risk of MS or NMOSD relapse after COVID-19 vaccination and infection","author":"Stastna","year":"2022","journal-title":"Multiple Sclerosis and Related Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib51","first-page":"1","article-title":"COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation","volume":"17","author":"Trinchillo","year":"2022","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23944_bib52","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s10072-021-05823-w","article-title":"Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review [J]","volume":"43","author":"Rodrigues","year":"2022","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23944_bib53","first-page":"1424","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review","volume":"28","author":"Tur","year":"2022","journal-title":"April 2021 [J]. Mult Scler"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23944_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12030407","article-title":"COVID-19 vaccination and neurological manifestations: a review of case reports and case series","volume":"12","author":"Sriwastava","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.heliyon.2023.e23944_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104102","article-title":"Vaccine hesitancy in people with multiple sclerosis","volume":"65","author":"Lechner-scott","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine hesitancy in the era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Publ. Health"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23944_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103359","article-title":"Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23944_bib58","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2213-2600(21)00559-2","article-title":"Omicron variant and booster COVID-19 vaccines","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.heliyon.2023.e23944_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.847873","article-title":"Factors affecting the intention of COVID-19 vaccination in Korean patients with myasthenia gravis: a survey-based study","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23944_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103236","article-title":"Vaccine hesitancy among people with multiple sclerosis","volume":"56","author":"Yap","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.heliyon.2023.e23944_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103723","article-title":"COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis","volume":"60","author":"Abbasi","year":"2022","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23944_bib62","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1212\/WNL.0000000000201376","article-title":"SARS-CoV-2 vaccination safety in guillain-barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy","volume":"100","author":"Baars","year":"2023","journal-title":"Neurology"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:19:15Z","timestamp":1790655555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023111522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023111522"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23944","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.168371479.91858877\/v1","asserted-by":"object"}]},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23944"}}